Neil Kumar, MD
Nephrology · Roseburg, ORNPI 1003813015
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $397,592 of the $531,702 with a category attached, or 74.8%. 51 manufacturers reported payments, led by Amgen at 24.5% of the total. Reporting peaked in 2019 at $203,897 and has fallen 90.1% since, to $20,172 in 2025. Among nephrology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,247 payments — averaging $426.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$130K
- AstraZeneca$125K
- Johnson & Johnson$61K
- Bayer$40K
- Otsuka America Pharmaceutical, Inc.$37K
- Shire North American Group Inc$36K
- plus $102K from 45 others
Across 24 payments — averaging $8024.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca AB$135K
- GSK$33K
- Hoffmann-la Roche Limited$10K
- Aurinia Pharma U.S., Inc.$10K
- Travere Therapeutics, Inc.$3K
- Astrazeneca UK Limited$1K
What the payments were for
- Consulting fees$22,3544%
- Speaking & faculty fees$397,59275%
- Travel & lodging$91,71717%
- Food & beverage$19,1124%
- Education$9270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$113,534
- FARXIGA$63,767
- INVOKANA$59,211
- LOKELMA$59,119
- Kerendia$39,538
- NATPARA (PARATHYROID HORMONE)$34,607
- JYNARQUE$34,192
- AURYXIA$29,909
- Velphoro$20,535
- Veltassa$11,679
- Parsabiv$8,909
- PURIFIED CORTROPHIN GEL$6,145
- XPHOZAH 30 MG$5,038
- Korsuva$4,605
- Tavneos$2,150
- Filspari$1,001
- SAMSCA$866
- Fabhalta$225
- SOLIRIS$150
- EVENITY$110
How this compares
$531,702 in reported general payments places this provider in the 95th percentile of 120 nephrology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FilspariSparsentan | 12 | $126,925 |
| MyrbetriqMirabegron | 84 | $64,350 |
| LokelmaSodium Zirconium Cyclosilicate | 84 | $64,136 |
| FarxigaDapagliflozin Propanediol | 73 | $47,803 |
| RayaldeeCalcifediol | 39 | $47,434 |
| VelphoroSucroferric Oxyhydroxide | 19 | $45,078 |
| JardianceEmpagliflozin | 38 | $37,956 |
| KerendiaFinerenone | 31 | $37,210 |
| Bumetanide | 591 | $30,226 |
| ProsolParenteral Amino Acid 20% No.1 | 222 | $24,128 |
| AuryxiaFerric Citrate | 14 | $22,181 |
| EntrestoSacubitril/Valsartan | 19 | $18,350 |
| Potassium Chloride | 1,033 | $16,137 |
| Sevelamer Carbonate | 68 | $11,785 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 53 | $11,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Travere Therapeutics, Inc.Filspari | $5,505 | $126,92512 claims |
| AstraZenecaLokelma, Farxiga | $125,369 | $111,940157 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $64,35084 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $311 | $47,43439 claims |
| Fresenius USA Marketing, Inc.Velphoro | $20,849 | $45,07819 claims |
| Boehringer IngelheimJardiance, Tradjenta | $71 | $44,47150 claims |
| BayerKerendia | $40,201 | $37,21031 claims |
| Akebia Therapeutics IncAuryxia | $30,818 | $22,18114 claims |
| NovartisEntresto | $520 | $18,35019 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $56 | $10,06015 claims |
| GSKTrelegy Ellipta | $167 | $6,99711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 nephrology providers in Oregon.
Other nephrology in Roseburg
- Anjali GuptaRoseburg$431
- Robert ProvenzanoPortland$45K
- Cyril KuriakoseTualatin$36K
- Nayan AroraPortland$23K
- Shalin SanghviSpringfield$20K
- Ramesh MarahattaSpringfield$19K
- Rupali AvasarePortland$16K
- David EllisonPortland$12K
- Shehzad RehmanPortland$10K
- Michael FeldmanBend$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.